Compounds > cycloviolacin o13
Page last updated: 2024-11-13

cycloviolacin o13

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cycloviolacin O13: amino acid sequence in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56673899
CHEMBL ID1801036
MeSH IDM0520084

Synonyms (2)

Synonym
cycloviolacin o13
CHEMBL1801036
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1660347Cytotoxicty against human PC3 cells after 24 hrs by MTT assay2020Journal of natural products, 06-26, Volume: 83, Issue:6
Exploring the Sequence Diversity of Cyclotides from Vietnamese
AID1825324Cytotoxicity against human SH-SY5Y cells assessed as cell viability at 5 uM upto 72 hrs by MTT assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide.
AID1825322Cytotoxicity against human U-87 MG cells assessed as cell viability using raw interpretation method2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide.
AID1825321Cytotoxicity against human SH-SY5Y cells assessed as cell viability using raw interpretation method2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide.
AID1825325Cytotoxicity against human U-87 MG cells assessed as cell viability at 5 uM upto 72 hrs by MTT assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide.
AID1660350Hemolytic activity in human red blood cells after 1 hr2020Journal of natural products, 06-26, Volume: 83, Issue:6
Exploring the Sequence Diversity of Cyclotides from Vietnamese
AID1825311Cytotoxicity against human SH-SY5Y cells using best fit nonlinear regression analysis2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide.
AID1660348Cytotoxicty against human HeLa cells after 24 hrs by MTT assay2020Journal of natural products, 06-26, Volume: 83, Issue:6
Exploring the Sequence Diversity of Cyclotides from Vietnamese
AID1660349Cytotoxicty against HUVEC after 24 hrs by MTT assay2020Journal of natural products, 06-26, Volume: 83, Issue:6
Exploring the Sequence Diversity of Cyclotides from Vietnamese
AID1825323Cytotoxicity against human U-87 MG cells using best fit nonlinear regression analysis2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide.
AID605685Hemolytic activity in human type A RBC assessed as hemolysis after 1 hr by microtitre plate2010Journal of natural products, Sep-24, Volume: 73, Issue:9
Isolation, sequencing, and structure-activity relationships of cyclotides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
temozolomide
[no description available]		2.4110imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
thidiazuron
[no description available]		2.1110ureas
kalata b1
kalata B1: a 29-residue cyclotide which has a cystine knot structure and beta-sheet; causes uterine contraction; the principal active component from Oldenlandia affinis; amino acid sequence given in first source		3.1510
kalata b2
kalata B2: conformation in first source		3.1510
cycloviolacin o2
[no description available]		2.7220
ConditionIndicatedRelationship StrengthStudiesTrials
Extravascular Hemolysis
[description not available]		02.2510
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		02.2510
Benign Neoplasms, Brain
[description not available]		02.4110
Astrocytoma, Grade IV
[description not available]		02.4110
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		02.4110
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.4110